30 results about "Acute onset" patented technology

A method for treating the lung during an acute episode of reversible chronic obstructive pulmonary disease such as an asthma attack. The method comprises transferring energy to an airway wall of an airway such that a diameter of the airway is increased. The energy may be transferred to the airway wall prior to, during or after an asthma attack. The energy may be transferred in an amount sufficient to temporarily or permanently increase the diameter of the airway. The method may be performed while the airway is open, closed or partially closed.

A method for treating the lung during an acute episode of reversible chronic obstructive pulmonary disease such as an asthma attack. The method comprises transferring energy to an airway wall of an airway such that a diameter of the airway is increased. The energy may be transferred to the airway wall prior to, during or after an asthma attack. The energy may be transferred in an amount sufficient to temporarily or permanently increase the diameter of the airway. The method may be performed while the airway is open, closed or partially closed.

The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.

Disclosed are methods of terminating acute episodes of cardiac arrhythmia, such as atrial fibrillation or ventricular fibrillation, in a mammal, such as a human, by administering to that mammal an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to terminate an acute episode of cardiac arrhythmia and/or restore normal sinus rhythm or heart rate. Also disclosed are methods of maintaining normal sinus rhythm or heart rate in a mammal, such as a human, and preventing a recurrence of an episode of cardiac arrhythmia in a mammal, by administering an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to maintain normal sinus rhythm or heart rate in a mammal that has experienced at least one prior episode of cardiac arrhythmia. Pharmaceutical compositions for use in these methods are also disclosed.

The invention belongs to the novel technical field of medicaments, and relates to a novel dosage form of ceftibuten for treating upper respiratory tract infections, such as pharyngitis, tonsillitis, scarlatina, parasinusitis and tympanitis; lower respiratory tract infections, such as acute bronchitis, acute onset of chronic bronchitis, pneumonia; urinary tract infection; enteritis and gastroenteritis. The novel dosage form is characterized in that the product is a sustained release capsule which slowly releases drugs in the water or prescribed release media at non-constant speed. Through the slow release, the drugs reach a stable blood concentration level in vivo, and the undesirable reactions and drug-resistant strains thereof are reduced.

The invention belongs to the technical field of medicaments, a chewable tablet of ceftibuten is used for treating upper respiratory tract infections, such as pharyngitis, tonsillitis, scarlatina, parasinusitis and tympanitis; lower respiratory tract infections, such as acute bronchitis, acute onset of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastroenteritis. The novel dosage form is characterized in that the product is a chewable tablet chewed or sucked in the mouth to dissolve for administration, and to take effect in the gastrointestinal tract or in the whole body through the absorption of the gastrointestinal tract.

Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.

The invention discloses the use of Bitongning preparation as medicament for the treatment of gout acute stages, wherein the Bitongning preparation is prepared from pseudo-ginseng and rhizoma corydalis as the raw materials.

The invention discloses a compound capable of reducing hypeluricemia and relieving gout symptoms in an acute attack period. The compound comprises probiotics, moringa powder and L-glutamine and has small side effects; the compound facilitates discharge of hypeluricemia and can regulate internal environments, regulate metabolic patterns and reduce blood uric acid; the compound can significantly reduce drastic inflammatory reactions, take effect within 10-12 h and greatly relieve and even completely eliminate swelling, heat pain, joint limitation and other symptoms in the acute attack period; the compound has very bright clinical application prospects.

The invention discloses an isosorbide 5-mononitrate nasal drug delivery composition for treating coronary heart diseases and angina, and a preparing method thereof. The nasal drug delivery composition comprises isosorbide 5-mononitrat, a solvent and a preservative, and optionally comprises an absorption enhancer, an osmotic pressure regulator and other pharmaceutic adjuvants. The composition has simple preparing process and stable and controllable quality, and is suitable for industrial production. The preparation is quickly absorbed, takes effect in 3-5 minutes, achieves the maximum drug effect after 15 minutes, has high bioavailability, convenient use, and good compliance of patients, is especially suitable for delivering drugs to the middle and old patients, dysphagia patients and bedrid patients, is suitable for delivering drugs for patients with coronary heart diseases and angina in acute attach period at the first time, obtains valuable time for rescuing patient lives, and has significant clinical meaning on long-term continuous prevention and maintenance therapy.

The present invention relates to methods for determining predisposition to apparent life-threatening events (ALTE) (also referred to as ''acute life threatening episodes'') and/or sudden infant death syndrome (SIDS) and in particular to methods of assessing potential susceptibility to development of ALTE and/or SIDS by determining a subject's total IgA and/or IgA1 level.

The invention discloses a pharmaceutical composition for treating idiopathic pulmonary fibrosis and application of such pharmaceutical composition. The pharmaceutical composition is prepared by compositing nafamostat and artesunate in a mass ratio of 1.6-2.4:1. Administration dosage for adults is 0.45-0.50mg/kg/day when the pharmaceutical composition is used for treating idiopathic pulmonary fibrosis. Clinical experiments show that the pharmaceutical composition is remarkably effective in treatment of acute idiopathic pulmonary fibrosis, subacute idiopathic pulmonary fibrosis, chronic idiopathic pulmonary fibrosis and acute onset of chronic idiopathic pulmonary fibrosis, reaches the total effective rate of 92-96%, and is capable of avoiding proneness to relapse and free of toxic or side effect, thereby being high in application value.

The invention relates to a traditional Chinese medicine for treating acute icteric hepatitis and acute-onset chronic hepatitis with increased bilirubin. The traditional Chinese medicine composition is prepared by 15 common traditional Chinese medicine materials which includes capillary artemisia, fructus gardeniae, rhubarb, prunella vulgaris, fructus schizandrae, rhizoma coptidis, cortex phellodendri, radix bupleuri, radix paeoniae alba, fructus aurantii immaturus, radix curcumae, endothelium corneum gigeriae galli, poria cocos, rhizoma atractylodis macrocephalae and radix glycyrrhizae. The traditional Chinese medicine has the advantages that the traditional Chinese medicine has effects of clearing heat and toxic material, disinhibiting dampness and relieving jaundice, promoting blood circulation to remove blood stasis, resisting inflammation, regulating immunity, protecting liver cells, and the like, can evidently lower aminotransferase and protect the liver cells, and can be used for treating the acute icteric hepatitis and the acute-onset chronic hepatitis; the compatibility of the traditional Chinese medicine conforms to the principle of 'monarch, minister, assistant and guide', and clinical application proves that the traditional Chinese medicine is evident in curative effect on the acute icteric hepatitis and the acute-onset chronic hepatitis with increased bilirubin; the traditional Chinese medicine is safe and effect, the preparation method of the traditional Chinese medicine is suitable for industrial production, and the traditional Chinese medicine is promising in application prospect.

Disclosed is a method of treatment of chronic obstructive pulmonary disease associated with chronic bronchitis in a patient at risk of exacerbations. The method includes administering to a patient with a history of chronic obstructive pulmonary disease associated with chronic bronchitis and at risk of exacerbations, a maintenance dose of 500 micrograms per day of roflumilast. Also disclosed is a method of increasing pre-bronchodilator FEV₁ or post-bronchodilator FEV₁ in such a patient, and increasing pre-bronchodilator FVC or post-bronchodilator FVC in such a patient. Further disclosed is a method of reducing the rate of exacerbations in such a patient.

The present invention relates to a compound medicine preparation for curing acute and chronic respiratory tract infection. It is made up by using azithromycin and phlegm-removing active component according to the weight mixing ratio of 1:0.05-2.

The invention belongs to the technical field of drugs. A suspension of ceftibuten is used for treating upper respiratory tract infections, such as pharyngitis, tonsillitis, scarlatina, parasinusitis and tympanitis; lower respiratory tract infections, such as acute bronchitis, acute onset of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastro-enteritis. The suspension is characterized in that the product is an insoluble solid medicament dispersed in the liquid media, each of 5ml containing ceftibuten of 0.05-1g, preferably 0.1-0.3g. The suspension is easy to administrate by children or dysphagia patients.

The invention relates to a heat-clearing, blood-cooling, stasis-removing and pain-stopping medicine for treating a gynecological leukorrheal disease caused by stagnant heat accumulation and a preparation method thereof, and belongs to the field of medicines. The medicine comprises the following raw materials in part by weight: 225-350 parts of honeysuckle stem, 225-350 parts of sargentg loryvine stem, 25-50 parts of liquorice, 75-200 parts of folium isatidis, 75-200 parts of dandelion, 75-200 parts of moutan bark, 75-200 parts of root of common peony, 75-200 parts of szechwan chinaberry fruit, 75-200 parts of rhizoma corydalis and 50-100 parts of rhubarb. The medicine can improve the body immunity, promote pelvic local blood circulation, improve the status of histotrophic nutrition and improve the metabolism so as to facilitate the absorption and elimination of inflammation and avoid reinfection or infection diffusion; and the medicine has a unique effect for patients whose states do not change for the better after long-time or repeated combined treatment of a variety of antimicrobial medicines or hormone medicines, especially for the young who need to preserve fertility, or during acute onset of the gynecological leukorrheal disease.